A World Of Opportunity For The Brave.
With all of the drama surrounding Novartis and Diovan, it seems that we are saying “sayonara” to the days of pharma blockbuster and moving on to a new chapter, one perhaps which will be written by specialty pharma.
Japan’s Health, Labor and Welfare Ministry committee recently released an interim report on the falsification of clinical research data involving Diovan, and while it is not known whether Novartis is actually responsible for manipulating research results, this is certainly a sad turn of events for one of the most respected foreign pharmaceutical companies in Japan. Diovan almost singlehandedly built the Swiss giant’s Japanese subsidiary in the hills of Azabu-Juban.
With the sales of Crestor, Diovan, Lipitor, Micardis, Blopress, and Tracleer all likely to fall off the patent cliff in the not-too-distant future, big pharma is scrambling to set up long-listed product divisions and established branded generics. Today, the sun is shining on specialty pharma.
The “twenty-tens” (2010-2019) are shaping up to be the decade of specialty pharma. The success stories of Alexion, Celgene, and Biogen-Idec are only precursors to the next generation of specialty pharma companies. Shire, Gilead, Ariad, and Leo Pharma have all planted their flags in the soil of the world’s second largest pharmaceutical market.
Alexion is a strong example of a specialty care pharma company that is doing very well in Japan. Alexion president Herman Strenger explains, “Alexion is developing and delivering life-transforming therapies for patients with severe and life-threatening disorders that are also ultra-rare. The only product Soliris has been approved in 2 indications, PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome). Both diseases are debilitating and life threatening and patients were left without any effective treatment options. With the availability of Soliris the outlook for patients has changed dramatically.”
The pharmaceutical market has also changed dramatically over the past 10 years. Many of the major companies have offered early retirement packages and are continuing to cut costs. Slowly, generics are gaining strength in the local market, and while this may not be occurring at the same level as in other markets, it is a trend that will continue. Once upon a time, Japanese subsidiaries could be insulated from the pressures facing global markets to some degree, but this is no longer the case, and business models are changing to accommodate the new reality.
The winners of the future appear to be the companies catering to unmet patient needs, such as Ikaria, which develops biotherapeutic solutions, nitric oxide for inhalation, and a vasodilator which treats hypoxic respiratory failure with concurrent pulmonary hypertension in neonates. “Ikaria is a critical care company that has been operating in Japan since 2009, providing a unique product – a drug/device/service package, called INOtherapy®, to hospitals throughout the country. The drug product, INOflo®, is the only Japanese Ministry of Health & Welfare-approved drug for hypoxic respiratory failure, and the offering provides neonatologists with a complete package to ensure this therapy is reliably delivered to Japanese infants born with this condition,” said Chris Hartz, Vice President and General Manager of Ikaria, K.K. “We are proud of our excellent product and our ability to impact the lives of infants in Japan”
Ikaria is swimming in a “blue ocean”. Blue ocean strategy suggests that organizations should create new demand in an uncontested market space, or a “blue ocean,” rather than compete head-to-head with other suppliers in an existing industry with heavy competition a “red ocean”.
Opportunities are bountiful for candidates too. Those candidates who have specialty pharma experience or expertise in these companies’ core functions will benefit the most. Big is not always best, and while many candidates have historically favored larger companies for their stability, perspectives are changing as it becomes clear that the light at the end of the tunnel is not the next diabetes drug but a drug treating a rare form of cancer or orphan disease. Moreover, while big pharma will always be on the lookout for exciting bio techs and specialty pharma businesses, fears about smaller companies being acquired and restructured have not come to pass. In smaller companies, investors and senior managers tend to have more faith in their products and prefer leaner business models, meaning that big pharma acquisition offers little benefit and it is often better to go it alone.
For a success story showing the viability of specialty care businesses, we need look no further than Biogen Idec Japan. When Morunda director Michael Huberts first began to work with the firm in 2006, there was resistance from some candidates about Biogen Idec’s long-term prospects. A common refrain at the time was, “They’ll soon be bought by X company or Y company.” This certainly wasn’t helped by the presence of billionaire investor/activist Carl Icahn who, at the time, owned roughly 8% of the company’s stock and was consistently pushing for it to find potential suitors. So what happened to the brave candidates that made the move to the company? Biogen Idec has grown from strength to strength, both globally and in Japan, where it has doubled in size. The company has a rich pipeline of products that tailor perfectly to patient needs and is now a highly attractive employer of choice in the Japanese market.
You may also enjoy
Morunda www.morunda.com should be your choice of recruiting partner in Japan and Asia Pacific. Why? Because we live and breathe the pharmaceutical industry in Asia and the Pacific—we’re specialists!
- Morunda has completed over 400 managers to director-level placements since 2001.
- A cultural understanding of what it takes to secure top talent
Over one hundred thought leadership articles published.
- We hold regular seminars for candidates and clients alike with industry experts.
- We understand the market, not only today, but where it is heading in the next 12 to 18 months